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Abstract
Aims: To evaluate changes in QT duration during low-dose haloperidol use, and determine associations between clinical
variables and potentially dangerous QT prolongation.
Methods: In a retrospective cohort study in a tertiary university teaching hospital in The Netherlands, all 1788 patients
receiving haloperidol between 2005 and 2007 were studied; ninety-seven were suitable for final analysis. Rate-corrected QT
duration (QTc) was measured before, during and after haloperidol use. Clinical variables before haloperidol use and at the
time of each ECG recording were retrieved from hospital charts. Mixed model analysis was used to estimate changes in QT
duration. Risk factors for potentially dangerous QT prolongation were estimated by logistic regression analysis.
Results: Patients with normal before-haloperidol QTc duration (male #430 ms, female #450 ms) had a significant increase
in QTc duration of 23 ms during haloperidol use; twenty-three percent of patients rose to abnormal levels (male $450 ms,
female $470 ms). In contrast, a significant decrease occurred in patients with borderline (male 430–450 ms, female 450–
470 ms) or abnormal before-haloperidol QTc duration (15 ms and 46 ms, respectively); twenty-three percent of patients in
the borderline group, and only 9% of patients in the abnormal group obtained abnormal levels. Potentially dangerous QTc
prolongation was independently associated with surgery before haloperidol use (ORadj 34.9, p=0.009) and before-
haloperidol QTc duration (ORadj 0.94, p=0.004).
Conclusion: QTc duration during haloperidol use changes differentially, increasing in patients with normal before-
haloperidol QTc duration, but decreasing in patients with prolonged before-haloperidol QTc duration. Shorter before-
haloperidol QTc duration and surgery before haloperidol use predict potentially dangerous QTc prolongation.
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Introduction
Haloperidol has for many years been a widely prescribed drug for
the treatment of agitation, delirium, acute and chronic psychoses.
Haloperidol is a butyrophenon antipsychotic that reduces psycho-
motor disturbances such as agitation and hallucinations by blocking
both dopamine D2 and a1-adrenergic receptors, causing an
antidopaminergic effect in the mesocortex and limbic system of the
human brain. Although haloperidol is effective in clinical practice, it
has been associated with QTc prolongation on the ECG
[1,2,3,4,5,6]. As QT prolongation is an established risk factor for
potentiallylife-threateningcardiac ventricular arrhythmiasofthe type
Torsade de Pointes [7,8,9,10], clinicians are advised to keep a keen
eye on (cardiac) medical history and QT interval changes when
treating patients with haloperidol [4,9,11]. QT prolongation by
haloperidol is ascribed to its blocking effects on the cardiac potassium
channel hERG and was shown in various clinical studies
[12,13,14,15]. Most clinical studies were performed in selected
healthy populations, or in sick patients with high intravenous doses
[6,16]. In clinical practice, however, haloperidol is mostly prescribed
orally at low doses to elderly patients with multiple co-morbidities.
Thus, clinicians are often faced with the need to prescribe haloperidol
to patients with other potential causes of QT prolongation, including
concomitant medication use and cardiac pathology (e.g., heart
failure). Yet, studies on QT prolongation during low-dosehaloperidol
use in such high-risk patients are lacking.
In this study, we examined whether there is an association
between haloperidol use and QT duration changes in a common
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ities and co-medications. By analyzing the ECGs of these patients
before, during and after haloperidol use, we studied whether QT
duration changed during the in-hospital use of haloperidol, taking
other clinical factors into account. Also, by comparing patient
characteristics and (acute) medical condition before haloperidol
use, we aimed to define patient groups at risk for dangerous QT
prolongation during haloperidol use. In particular, given that
hospitalized elderly patients are often given haloperidol because
they are agitated during an acute phase response, after surgery, or
during acute hospitalization [17,18], we studied whether these
factors may impact on a patient’s QTc response to haloperidol.
Methods
Study population and design
In this retrospective cohort study, we used a database of all 1788
in-hospital patients for whom haloperidol was prescribed between
2005 and 2007 during admission at the Academic Medical Centre,
a university teaching hospital in Amsterdam. We analyzed all
patients (N=237) of whom three ECG recordings were made
before, during and after haloperidol prescription, i.e., i) between
two weeks and one day before start of haloperidol, ii) between one
hour after start of haloperidol and 24 h after the last dose of
haloperidol, and iii) .one week after the last dose of haloperidol
[19,20].
The study was conducted according to the principles expressed
in the Declaration of Helsinki. All data were retrieved from the
hospital’s databases (where data of routine clinical care measures
are stored) and were analysed anonymously. The medical ethics
committee of the Academic Medical Center (Amsterdam) waived
the need for approval and informed consent.
Measurements
ECG analysis was conducted while the researchers were blinded
for haloperidol status. QT durations were measured by hand and
corrected for heart rate using Bazett’s formula (QTc). All three
measurements (before-haloperidol ECG, during-haloperidol ECG,
and after-haloperidol ECG) were analyzed in the same lead for
each patient, based on the best readable recording. In case of atrial
fibrillation or irregular heart rates, the mean of all RR intervals in
the recording was used for rate correction. Patients who had ECGs
with multiple ventricular extrasystoles, pacemaker beats, left or
right bundle branch block, or whose QTc duration could not be
reliably measured (typically due to flat T waves) were excluded
from further analysis. Of each patient, we obtained the following
information from the hospital records: gender, age, medical
history, medical status during hospital admission before haloper-
idol use (e.g., reason of admission, any surgery for which general
anesthesia was given within 3 days before haloperidol use), actual
administration and given dose of haloperidol, and the use of other
QT prolonging drugs (CERT list 1 [21]) within the 72 hours
before each ECG recording. We collected data of electrolytes
measured within 48 hour before or after each ECG recording,
using the measurement closest to the moment of recording, or
within 24 hours of the recording moment in the case of serum
potassium values. Signs of an acute phase response or inflamma-
tion at the time of each ECG recording were defined as either
body temperature .39uC, or serum CRP level .100 mg/l, or
leukocyte count .100*10E9/L. To analyze whether the QTc
duration before haloperidol use influenced the levels of change in
QTc duration, we stratified the patients into three subgroups of
before-haloperidol QTc duration, based on the European Society
of Cardiology Guidelines [22]: 1) Normal (male #430 ms, female
#450 ms), 2) Borderline (male 431–450 ms, female 451–470 ms),
and 3) Abnormal (male .450 ms, female .470 ms).
Data analysis
Statistical Package for the Social Sciences (SPSS, version 16.0
for Mac) was used for data analysis. Changes in mean QTc
duration before, during and after haloperidol use, and differences
in the change of QTc duration per subgroup were tested for
significance using a mixed model analysis assuming fixed effects,
thereby accounting for changes in relevant clinical factors. We
evaluated associations with patient variables, haloperidol dose, co-
medication, medical history, medical status during hospital
admission, electrolyte levels, and ECG parameters. Factors that
were univariately associated (p,0.25) with before-haloperidol
QTc duration, change in QT duration, or subgroup stratification
were entered in the mixed model analysis. The final model
estimated changes in QTc duration while accounting for relevant
variables (backward selection with p,0.05). To test the possibility
that an above normal QRS width influenced observed QTc
duration, we performed a second analysis in which we did not use
the measured QTc duration as the dependent variable, but the
QTc duration minus excess QRS duration (i.e., QRS width minus
110 ms).
Risk factors for potentially dangerous QTc prolongation were
analyzed using logistic regression in SPSS. Potentially dangerous
QTc prolongation was defined as an increase in QTc duration by
.50 ms or to .500 ms, or the occurrence of Torsade de Pointes
[23]. Factors that were associated with a p,0.05 in the univariate
analyses were entered into the multivariate models. Effect sizes
were expressed in odds ratios (OR) with their corresponding 95%
confidence intervals (CI) and p-values. Data are expressed as
mean6standard deviation (SD), unless otherwise indicated.
Results
From a total cohort of 1788 patients for whom haloperidol was
prescribed between 2005 and 2007 (mean age 67 years, male
59%), we first extracted all patients of whom an ECG recorded
before, during, and after haloperidol prescription was available;
this yielded 237 patients (mean age 70 years, male 66%). Since the
prescription of haloperidol often reads ‘when necessary’, we
verified in the patient’s medical charts whether haloperidol was
actually administered, and whether the ECG was recorded during
actual haloperidol use. We excluded 81 patients of whom we could
not establish this (Figure 1). We further excluded 59 patients
because of ECG abnormalities that hindered a valid and reliable
measurement of QT duration, yielding a study population of 97
patients for final analysis (mean age 68 years, male 64%). In case
of missing data of serum levels of sodium or potassium, we
imputed the mean value.
Table 1 presents baseline characteristics of the study population.
Thirty to 41% of patients in the three subgroups underwent
surgery and 70–78% had signs of inflammation. Subgroup
stratification by QTc duration before haloperidol use was
significantly associated with gender (more males in abnormal
group, p=0.002) and QRS interval (p=0.049), but with none of
the other measured conditions. Dose of haloperidol was 2,6 mg
per day on average, (range: 0.5–10 mg per day), and was given
orally in 75% of patients and intravenously in 25% of patients.
When we studied mean QTc duration of our overall study group,
we found no change in QTc duration upon haloperidol use
(Figure 2) and a decrease (212.1648.9 ms [p=0.017]) after
discontinuation of haloperidol. When we analyzed subgroups
stratified by before-haloperidol QTc duration (normal, borderline
Changes in QTc Duration during Haloperidol
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QTc prolongation during haloperidol use (mean increase
23.1645.5 ms [p,0.001], Figure 1). Twenty-three percent of these
patients rose to abnormal levels. In contrast, the subgroups with
borderline and abnormal before-haloperidol QTc duration showed
significant QTc shortening upon haloperidol use (borderline:
214.6626.2 ms [p=0.035], and abnormal: 245.9655.5 ms
[p=0.001]). Twenty-three percent of patients in the borderline
group, and nine percent of patients in the abnormal group obtained
abnormal levels. After discontinuation of haloperidol, all three
groupsshoweda decreaseinQTcduration(normal:29.1647.7 ms
[p=0.156]; borderline: 211.4643.9 ms [p=0.298]; abnormal:
220.0656.0 ms [p=0.101]).
Differences in QTc duration were found significant in the final
mixed models analysis when comparing QTc durations before and
during the use of haloperidol in the normal and abnormal
subgroups, after adjusting for relevant covariates (signs of infection
and surgery before haloperidol use). Changes in QTc duration
after haloperidol discontinuation were not significant. Overall, the
course of the changes in QTc duration was significantly different
for each subgroup (p,0.001). Repeating the analysis with QRS-
duration subtracted from the measured QTc duration did not
yield different results.
In total, 16 patients (16%) developed potentially dangerous QTc
prolongation during haloperidol use, 15 (94%) of whom had a
normal before-haloperidol QTc duration. In only 2 patients QTc
duration increased to .500 ms. No episodes of Torsade de
Pointes were found.
We analyzed factors associated with dangerous QTc prolonga-
tion (Table 2). Five risk factors showed significant ORs in the
univariate analysis (gender, before-haloperidol QTc duration,
heart rate, surgery before haloperidol use, and signs of
inflammation before haloperidol use), and were subsequently
entered in the multivariate analysis. ORs and their corresponding
95% confidence intervals are presented in Table 2. Surgery before
haloperidol use was strongly associated with increased risk of
potentially dangerous QTc prolongation (OR 34.9 [p=0.009]), as
was male gender (OR 7.6 [p=0.055]), though the latter not
statistically significantly. Longer before-haloperidol QTc duration
(OR 0.94 [p=0.004]), faster before-haloperidol heart rate (OR 0.9
[p=0.029]) and signs of inflammation (OR 0.1 [p=0.147]) were
associated with reduced risk of QTc prolongation, though not
statistically significant for inflammation. In contrast, dose of
haloperidol, mode of administration, and presence of cardiovas-
cular risk factors were not associated with potentially dangerous
QTc interval prolongation (only heart failure and ischemic heart
disease increased the risk, though not statistically significantly).
The model estimated 90.7% of the cases correctly.
Discussion
In this real-life study among hospitalized elderly patients with
multiple co-morbidities, we found that substantial QTc prolongation
upon low-dose haloperidol use occurred predominantly in patients
with normal before-haloperidol QTc duration. Conversely, in most
patients with borderline or abnormal before-haloperidol QTc
duration, an unexpected QTc shortening occurred. Importantly,
94% of patients with potentially dangerous QTc prolongation had a
before-haloperidol QTc duration in the normal range. A rise in QTc
duration to potentially dangerous levels was not only associated with
before-haloperidol QTc duration, but also with surgery (increased
risk)andsignsofinflammation(decreasedrisk)beforehaloperidoluse.
Although patients with cardiovascular risk factors are reported to
have a higher risk of QTc prolongation [24,25], we did not find
significant associations in our study population.
It is unlikely that QTc shortening in patients with a prolonged
QTc interval prior to haloperidol use is due to the effects of
haloperidol per se. A more plausible explanation might be that
Figure 1. Flowchart of patient inclusion.
doi:10.1371/journal.pone.0023728.g001
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use, and that these changes caused QTc duration to shorten,
despite haloperidol use. For instance, although speculative, it is
possible that the complex effects of acute illness (both cardiac and
non-cardiac), acute phase response, or poor general condition
(e.g., post-operative patients), contributed to QTc prolongation
through as yet unknown mechanisms. In support of the view that
acute illness may cause QTc prolongation, average QTc durations
of all three subgroups were normal after haloperidol use, i.e., when
the acute illness had subsided.
Unexpectedly, potentially dangerous QTc-prolongation was
associated with absence of signs of inflammation, though not
Table 1. Baseline characteristics of patients: all, and stratified in subgroups based on QTc duration before haloperidol.
All patients (N=97) Normal (N=57) Borderline (N=17) Abnormal (N=23)
Male, n (%)* 62 (63.9) 29 (50.9) 12 (70.6) 21 (91.3)
Age, years, mean (SD) 67.7 (14.3) 68.2 (14.5) 66.1 (15.8) 67.4 (13.5)
Dose of haloperidol, mean (SD) 2.6 (2.2) 2.5 (2.3) 2.3 (1.9) 3.1 (2.1)
QTc duration, ms, mean (SD)* 433.6 (43.2) 408.8 (24.6) 444.4 (11.3) 487.0 (43.0)
Heart rate, beats per minute, mean (SD) 86.8 (25.6) 85.0 (23.9) 98.0 (31.0) 83.1 (24.0)
QRS width, ms, mean (SD) 93.2 (15.1) 91.3 (14.9) 91.8 (16.2) 99.0 (13.7)
Serum sodium level, mmol/l, mean (SD) 139.8 (3.6) 139.5 (3.8) 140.5 (3.9) 140.0 (2.9)
Serum potassium level, mmol/l, mean (SD) 4.1 (0.5) 4.1 (0.4) 4.3 (0.5) 3.9 (0.6)
Diabetes, n (%) 20 (20.6) 12 (21.1) 4 (23.5) 4 (17.4)
Hypertension, n (%) 41 (42.3) 22 (38.6) 9 (53.9) 10 (43.5)
Heart failure, n (%) 11 (11.3) 5 (8.8) 3 (17.6) 3 (13.0)
Ischemic heart disease, n (%) 54 (55.7) 31 (54.4) 9 (52.9) 14 (60.9)
Surgery before haloperidol use, n (%) 36 (37.1) 22 (38.6) 7 (41.2) 7 (30.4)
Signs of inflammation, n (%) 70 (72.2) 40 (70.2) 12 (78.3) 18 (78.3)
Use of QT interval prolonging drugs, n (%) 6 (6.2) 3 (5.3) 0 (0) 3 (13.3)
Normal QTc duration: male ,430 ms, female ,450 ms,; borderline QTc duration: male 431–450 ms, female 451–470 ms;
abnormal QTc duration: male .450 ms, female .470 ms.
*Significant differences between subgroups (p,0.05).
doi:10.1371/journal.pone.0023728.t001
Figure 2. Course of changes in QTc duration before, during and after haloperidol use. Mean QTc intervals before, during and after
haloperidol use of total patient group and of each subgroup, with Standard Errors of the mean. Normal: male #430 ms, female #450 ms, borderline:
male 431–450 ms, female 451–470 ms, abnormal: male .450 ms, female .470 ms. B: before haloperidol use, D: during haloperidol use, A: after
haloperidol use. * indicates significant change at p,0.05 level.
doi:10.1371/journal.pone.0023728.g002
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is suggested as a risk factor for QTc prolongation in patients with a
decreased hERG function (e.g., patients using QT prolonging
drugs) [17,26]. Proposed mechanisms include the effects of
circulating inflammatory cytokines on ionic currents that deter-
mine QT duration, and increased drug-mediated block of hERG
channels at high temperature, as demonstrated for erythromycin
[27,28]. It is conceivable that inflammation/fever and haloperidol
may act in an additive manner in blocking the hERG channel,
thus causing clinically dangerous QTc prolongation. Yet, we
observed that signs of inflammation decreased the risk for
potentially dangerous QTc prolongation. Thus, the presence of
inflammation before haloperidol use was not associated with
potentially dangerous QTc prolongation during haloperidol use.
One possible explanation may be that the QT prolonging effect of
inflammation in these patients was stronger than that of
haloperidol. Thus, attenuation of the inflammation between the
before-haloperidol state and the during-haloperidol state may have
been associated with attenuation of the QT prolonging effects of
inflammation (i.e., QT shortening); this effect may be stronger
than the QT prolonging effect of haloperidol; the net result would
be QT shortening (or lack of further QT prolongation).
A limitation of our study is that the patients had different causes
and stages of inflammation or acute phase response; thus, different
levels and types of circulating cytokines may have been present.
Therefore, it remains difficult to link the changes in QT duration
during haloperidol use directly to the effects of inflammation.
Moreover, the indication for haloperidol prescription (e.g.,
agitation) may also be associated with QTc prolongation,
independent of haloperidol use. This may be the case in post-
operative patients, who, in our population, are at increased risk to
develop potentially dangerous QTc prolongation. A stress
response has been shown to induce QTc prolongation [29],
which may, at least in part, explain our findings. Further research
is needed to establish whether the various indications for
haloperidol prescription in elderly hospitalized patients are
associated with changes in QTc duration, and to elucidate the
underlying mechanisms of these changes.
To our knowledge, this is the first study that attempts to
evaluate changes in QTc duration upon haloperidol use, while
taking co-morbidities that play an important role in a real-life
clinical setting into account. A major limitation of our study,
however, is its retrospective design. By limiting our study to
patients of whom ECG-recordings were available before, during
and after haloperidol use, we excluded patients who were
discharged or died during haloperidol use. Moreover, we were
biased towards patients in whom multiple ECG recordings were
made, thereby probably introducing an overrepresentation of
patients with cardiac disease. This might explain the large
proportion of male patients in our study population.
Our findings would seem to suggest that ECG monitoring of
elderly patients who receive in-hospital low-dose haloperidol may
not be necessary, as QTc prolongation occurred mostly in patients
with normal before-haloperidol QTc duration, while QTc
duration generally shortened in those with before-haloperidol
QTc prolongation. Overall, potentially dangerous QTc prolon-
gation occurred only in few patients, and Torsade de Pointes was
recorded in none. Yet, we see the largely surprising findings of our
study (in particular, the differential effects between subgroups) as
indication that the real-life clinical effects of haloperidol are not
well-established. We therefore conclude that more research (larger
prospective studies) is needed to allow for rational clinical decision
making on the cardiac safe use of haloperidol.
Table 2. Unadjusted and adjusted Odds Ratios for potentially dangerous QTc prolongation.
Variable
Potentially dangerous QTc
prolongation Univariate Multivariate I*
Yes (n=16) No (n=81) OR 95% CI p-value OR* 95% CI p-value
Male, n (%) 14 (87.5) 48 (59.3) 4.8 1.0–22.6 0.046 7.6 1.0–60.5 0.055
Age years, mean (SD) 70.5 (9.7) 67.1 (15.1) 1.0 1.0–1.1 0.380
Dose of haloperidol, mg, mean (SD) 2.4 (2.2) 2.6 (2.2) 0.9 0.7–1.2 0.682
Before-haloperidol QTc, ms, mean (SD) 401.8 (24.4) 439.8 (43.4) 0.97 0.95–0.99 0.001 0.94 0.91–0.98 0.004
Normal QTc, n (%)** 15 (26.3) 42 (73.7)
Borderline QTc, n (%)** 0 (0.0) 17 (100) n.a.
Abnormal QTc, n (%)** 1 (4.3) 22 (95.7) 0.1 0.0–1.0 0.053
Heart rate, beats per min., mean (SD) 68.4 (15.3) 90.5 (25.7) 0.9 0.9–1.0 0.004 0.9 0.8–1.0 0.029
QRS width, ms, mean (SD) 99.1 (14.9) 92.0 (14.9) 1.0 1.0–1.1 0.090
Serum sodium level, mmol/L, mean (SD) 139.9 (3.2) 139.7 (3.9) 1.0 0.9–1.2 0.860
Serum potassium level, mmol/L, mean (SD) 4.1 (0.4) 4.1 (0.5) 0.9 0.3–2.7 0.876
Diabetes, n (%) 2 (12.5) 14 (17.3) 0.5 0.1–2.4 0.387
Hypertension, n (%) 6 (37.5) 35 (43.2) 0.8 0.3–2.4 0.673
Heart failure, n (%) 3 (18.8) 8 (9.9) 2.1 0.5–9.0 0.315
Ischemic heart disease, n (%) 10 (62.5) 44 (54.3) 1.4 0.5–4.2 0.548
Surgery before haloperidol use, n (%) 13 (81.2) 23 (28.4) 10.9 2.8–41.9 ,0.001 34.9 2.4–506.2 0.009
Signs of inflammation, n (%) 7 (43.8) 63 (77.8) 0.2 0.1–0.7 0.008 0.1 0.0–1.1 0.147
Use of QT interval prolonging drugs, n (%) 2 (12.5) 4 (4.9) 2.7 0.5–16.5 0.268
OR: Odds Ratio, CI: confidence interval, SD: Standard Deviation, n.a.: not applicable.
*Multivariate I: ORs in the multivariate analysis are adjusted for gender, baseline QTc duration in ms, heart rate, surgery before haloperidol, and signs of inflammation.
doi:10.1371/journal.pone.0023728.t002
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